Yang S, Emelyanov A, You MS et al (2020) Camel regulates development of the brain ventricular system.Details of MKV and MP4 file format Format Wu LP, Ahmadvand D, Su J et al (2019) Crossing the blood–brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide. Wright P, Nogueira G, Levin E (1971) Role of the pia mater in the transfer of substances in and out of the cerebrospinal fluid. Wang P, Zheng X, Guo Q et al (2018) Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer’s disease. Verma A, Hesterman J, Chazen J et al (2020) Intrathecal 99mTc-DTPA imaging of molecular passage from lumbar cerebrospinal fluid to brain and periphery in humans. Van Rooy I, Hennink WE, Storm G, Mastrobattista E et al (2012) Attaching the phage display-selected GLA peptide to liposomes: factors influencing target binding. Tietz S, Engelhardt B (2015) Brain barriers: crosstalk between complex tight junctions and adherens junctions. Tang B, Li Z, Huang D et al (2013) Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library. Sun C, Xu B, Lu Z et al (2009) Analysis of curative effect of intracranial infections after craniotomy treated with intrathecal vancomycin. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Scheltens P, Blennow K, Breteler MM et al (2016) Alzheimer’s disease. Reynolds JL, Mahato RI (2017) Nanomedicines for the treatment of CNS diseases. Miller L, Michel J, Vogt G et al (2014) Identification and characterization of a phage display-derived peptide for orthopoxvirus detection. Méndez-Gómez HR, Galera-Prat A, Meyers C et al (2015) Transcytosis in the blood-cerebrospinal fluid barrier of the mouse brain with an engineered receptor/ligand system. Majerova P, Hanes J, Olesova D et al (2020) Novel blood–brain barrier ShuttlePeptides discovered through the phage display method. Luo Z, He Y, Ma G et al (2020) Years of life lost due to premature death and their trends in people with malignant neoplasm of female genital organs in Shanghai, China during 1995–2018: a population-based study. Li J, Feng L, Jiang X (2015) In vivo phage display screen for peptide sequences that cross the blood-cerebrospinal-fluid barrier. Koivunen E, Gay DA, Ruoslahti (1993) Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. Kim H, Na DL, Lee NK et al (2020) Intrathecal injection in a rat model: a potential route to deliver human Wharton’s jelly-derived mesenchymal stem cells into the brain. Keaney J, Campbell M (2015) The dynamic blood-brain barrier. Householder KT, Dharmaraj S, Sandberg DI et al (2019) Fate of nanoparticles in the central nervous system after intrathecal injection in healthy mice. Haley MJ, Lawrence CB (2017) The blood-brain barrier after stroke: structural studies and the role of transcytotic vesicles. Gao H, Yang Z, Zhang S et al (2018) Internalization and subcellular fate of aptamer and peptide dual-functioned nanoparticles. Eur J Surg Oncol 47(3 Pt A):597–602īakhshinejad B, Zade HM, Shekarabi HS et al (2016) Phage display biopanning and isolation of target-unrelated peptides: in search of nonspecific binders hidden in a combinatorial library. Mol Immunol 102:26–31īacken A, Lamarca A, Hubner RA et al (2021) HPB cancers in older patients|inclusion of older/senior patients in clinical trials. A peptide sequence denoted as PMK, which was demonstrated to be able to cross the BCSFB via in vivo optical imaging analysis, could be used in the future for the construction of targeted drug delivery systems.Īlexander JJ (2018) Blood-brain barrier (BBB) and the complement landscape. Several bacteriophage clones from the final round were randomly selected and sequenced. After several rounds of screening, the candidate phages that could cross the BCSFB were enriched. We applied a phage seven-mer cyclic peptide library (Ph.D.-C7C™) intravenously to rats and later recovered phages from the CSF. In this study, phage display technology was effectively applied to screen novel peptides as targeting motifs to transport drugs across the blood-cerebrospinal fluid barrier (BCSFB). Compared with the BBB, drugs may have a better likelihood of reaching the brain via the cerebrospinal fluid (CSF) because of the lack of a barrier between the CSF and the brain. Treatments of brain diseases are heavily limited by the existence of the blood–brain barrier (BBB), which precludes efficient drug delivery to the brain.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |